From the authors'650,000 compound collection, they have selected approximately 15,000 potential small-molecule protease inhibitors, which were subjected to high-throughput screening against caspase-3. The screening yielded a series of hits that belong to 11 different scaffolds. Based on the structure of one of the hits, a new class of the small-molecule inhibitors with a double electrophilic warhead, 8-sulfonyl-pyrrolo[3,4-c]quinoline-1,3-diones (SPQ), was synthesized and tested in follow-up mechanistic and antiapoptosis assays. Mechanistic analysis of a representative compound of this class, CD-001-0011, showed that the compound exhibited a high potency (IC 50 = 130 nM), was reversible though noncompetitive, and had a broad selectivity profile to other caspases belonging to groups I to III. The compound was effective in preventing staurosporineinduced apoptosis in a few cell lines and retinoic acid-induced apoptosis in zebrafish. (Journal of Biomolecular Screening 2006:277-285) 
INTRODUCTION
A POPTOSIS, OR PROGRAMMED CELL DEATH, is a normal component of the development and health of organisms. Cells die in response to a variety of stimuli, and during apoptosis, they do so in a controlled, regulated fashion. Apoptosis is a process in which cell-signaling mechanisms play an active role in the cell's own death without triggering inflammation. This makes apoptosis distinct from other forms of cell death, such as necrosis, in which uncontrolled cell death leads to cell lysis, release of intracellular content, triggering of inflammatory responses, and, potentially, serious health problems.
A major biochemical pathway involved in apoptosis includes a family of proteases, known as caspases, which act in a cascade to activate downstream caspases responsible for breakdown or cleavage of key cellular substrates required for normal cellular function, including structural proteins in the cytoskeleton and nuclear proteins such as DNA repair enzymes.
Caspases are found practically in all organisms from Caenorhabditis elegans to humans. 1 At least 12 of the caspases have been cloned (caspases 1 through 10, 13, and 14). 2,3 Caspases 11 and 12, 2 murine homologs, have no known human counterpart. Two major functionally distinct groups of the caspases are currently recognized as participating in either inflammation or apoptosis. Caspases share similarities in amino acid sequence, structure, and substrate specificity 4 and are subdivided into 2 subfamilies based on their functionality: caspases involved in inflammation (caspases 1, 4, 5, 11, 12, 13, and 14) and apoptosisrelated caspases (caspases 2, 3, 6, 7, 8, 9, and 10) . Based on their position in the apoptotic signal pathway, the subfamily of apoptosis-related caspases has also been subdivided into 2 groups: initiator caspases (caspases 2, 8, 9, and, probably, 10) and executioner (or effector) caspases (caspases 3, 6, and 7). 5 Activation of caspase-3 is a key event integrating upstream signals into final execution of cell death. This makes caspase-3 an interesting therapeutic target, and the search for caspase-3 inhibitors is an ongoing endeavor many pharmaceutical companies are embracing in the search for effective drugs. [6] [7] [8] [9] As an alternative to the 2 extremes of drug discovery-purely rational drug design and blind screening campaigns-in silico computational docking has resulted in the design and synthesis of novel small-molecule inhibitors of cysteinyl proteases, including caspases. Different classes of the reversible and irreversible protease inhibitors discovered through these efforts are described in Schirmeister and Kaeppler. 10 Screening of a protease-focused li-brary that we have assembled from our internal collection of more than 650,000 compounds yielded several new classes of smallmolecule caspase-3 inhibitors. In this report, we describe mechanistic and selectivity profiles of a new series of potent nonpeptide inhibitors, as well as their cell-based and zebrafish antiapoptotic action.
MATERIALS AND METHODS

Reagents
Caspase-3 was purchased from Upstate USA (Charlottesville, VA). Caspases 1, 4 to 6, and 9, Ac-WEHD-AMC, Ac-WEHD-AMC, and Ac-WEHD-AMC were from Calbiochem (San Diego, CA). Caspases 2, 7, 8, and 10 were from R & D Systems (Minneapolis, MN). Ac-DEHD-AMC, Ac-VEHD-AMC, Ac-IETD-AMC, Ac-VEHD-AMC, and Ac-IETD-AMC were from Sigma (St. Louis, MO), and Ac-DEVD-AMC and Ac-DEVD-AMC and Ac-DEVD-CHO were from Bachem (King of Prussia, PA). All other reagents were of a research grade.
Library selection
We used our "focused diversity" approach to select 15,338 compounds from our 650,000 compound collection for screening against caspase-3. In accordance with this approach, one of the selection criteria was based on the warhead concept, [11] [12] [13] with a modification to include only electrophilic compounds with reversible formation of chemical bonds. As the active site of caspase-3 contains a sulfhydryl moiety necessary for its catalytic activity, we focused the selection on molecules with the warheads capable of reacting with the cysteinyl thiols. At the same time, the core of the molecules was represented by a diversity of heterocyclic structures such as quinoxalinones, pyridones, pyrimidinones, pyrimidinediones, qiunolones, and so forth.
Enzyme assay
The assay buffer contained 2 mM EDTA, 0.1% Chaps, 20 mM HEPES pH 7.4, and 5 mM DTT. Thirty microliters of the substrate, 50 µM Ac-DEVD-AMC, and 30 µL of 0.7 U/µL caspase-3 were added to the microplates. The enzymatic activity of the caspase-3 was measured at ambient temperature by registering the timedependent accumulation of the fluorescent product, methylcoumarine, which is formed during cleavage of the fluorogenic substrate, Ac-DEVD-AMC. Our data (not shown) indicated linearity of the Ac-DEVD-AMC cleavage for up to 10 h, indicating absence of a product inhibition or plate reader photomultiplier saturation. Caspase-3 was freshly prepared from a frozen stock by diluting with the assay buffer. Activities of the other caspases were measured similarly using the corresponding fluorogenic substrates: Ac-WEHD-AMC for caspase-1, Ac-DEHD-AMC for caspase-2, Ac-WEHD-AMC for caspase-4, Ac-WEHD-AMC for caspase-5, Ac-VEID-AMC for caspase-6, Ac-DEVD-AMC for caspase-7, Ac-IEPD-AMC for caspase-8, and Ac-LEHD-AMC for caspase-9.
Reversibility of inhibition assay
Thirty microliters of caspase-3 (14 U/µL) in assay buffer containing 5 mM DTT was mixed with 30 µL of 3 µM CD-001-0011 (the final compound concentration of 1.5 µM is approximately 10fold higher than its IC 50 ). The mixture was incubated for 1 h at room temperature and then diluted 10-fold with the assay buffer. The substrate was added as described above to the diluted aliquots taken at the indicated time points. As a control, a mixture of caspase-3 and CD-001-0011 (0.7 U/µL and 0.15 µM, respectively) was prepared and incubated for the same time durations before addition of the substrate.
Cell apoptosis assay
SH-S5Y5 (human neuroblastoma), Jurkat (human T-cell leukemia), and NIH-3T3 (mouse embryonic fibroblast) cell lines were obtained from ATCC. SH-S5Y5 cells were cultured in DMEM/F-12 medium with L-glutamine, HEPES, and pyridoxine (Invitrogen, Carlsbad, CA). Jurkat and NIH-3T3 cells were cultured in RPMI-1640 medium with L-glutamine (Invitrogen). All culture media were supplemented with 10% fetal bovine serum (NovaTech) and antibiotic/antimycotic solution (Sigma). Cells were grown at 37°C in 5% CO 2 /95% air environment at 100% humidity.
SH-S5Y5 and HIH-3T3 cells were plated into half-area wells of 96-well cell culture plates (Corning, Corning, NY) at 10 4 cell/well in 45 µL of medium and grown overnight before compound addition. Jurkat cells were plated in 45 µL/well of serum-free hybridoma medium (Invitrogen) at 2.5 × 10 5 cells/mL and incubated for 1 h before compound addition. A total of 10 mM DMSO stock compound solutions was diluted 1:10 with growth medium, and 5 µL of the resulting 1 mM (10% DMSO) compound solutions was added to the cells. Ten percent DMSO was also used for control (no compounds) wells. Cells were incubated for 30 min before addition of 5 µL of the apoptosis inducer staurosporine (final concentration of 100 nM). After 24 or 48 h of incubation, Alamar Blue ® reagent (Biosource, Camarillo, CA) was added at 5.5 µL/ well. Cells were further incubated for 90 min, and the fluorescence of converted Alamar Blue ® dye was measured using the Wallac Victor 2 V plate reader (PerkinElmer, Wellesley, MA) at 531/589 nm ex/em wavelengths. The percent protection from induced apoptosis was calculated using the following equation:
where ∆Fl denotes the difference in Alamar Blue ® fluorescence measured at point 0 and after 90-min incubation with the cells; subscripts i, s, and o define, respectively, fluorescence in the presence of a compound and staurosporine, staurosporine alone, and no staurosporine.
Zebrafish apoptosis assay
Embryo collection. Zebrafish experiments were performed by Phylonix Pharmaceuticals, Inc. Embryos were generated by natural pairwise mating in accordance with the work of Westerfield. 14 Embryos were maintained at 28°C in fish water (200 mg Instant Ocean Salt; Aquarium Systems, Mentor, OH) per liter of deionized water, pH 6.6 to 7.0, maintained with 2.5 mg/L Jungle pH stabilizer (Jungle Laboratories Corporation, Cibolo, TX; conductivity 670-760 µS). Embrions were used for the experiments 24 h postfertilization (hpf).
Embryo treatment. Ten embryos were used for each regimen: 1) control (1% DMSO) 24-hpf embryos, 2) retinoic acid + 1% DMSO-treated 24-hpf embryos, and 3) retinoic acid plus compound-treated 24-hpf embryos. Treatment duration was 24 h. Thus, apoptosis in the forebrain region was examined at 48 hpf.
Visualization of apoptotic cells in forebrain.
Zebrafish were immersed in 1 µg/mL acridin orange in phosphate-buffered saline for 1 h and rinsed twice in 10 mL of fresh fish water. Fish were anesthetized in MESAB (0.5 mM 3-aminobenzoic acid ethyl ester, 2 mM Na 2 HPO 4 ) and mounted in methylcellulose in depressed slides for observation with a Zeiss M2Bio fluorescence microscope (Carl Zeiss Microimaging Inc., Thornwood, NY).
Compound screening
A library of small molecules (about 15,000 compounds) with purity higher than 95% was screened in a 384-well plate format. A BiomekFX Assay Work Station (Beckman Coulter, Fullerton, CA) was used for plate formatting and reagent distribution. Fluorescence measurements were performed using a VICTOR 2 V 96/ 384 multilabel plate reader (PerkinElmer Life Sciences, Boston, MA) at λ ex = 360 nm and λ em = 460 nm (top readout) in Corning black 384-well plates.
A total of 195 µL of the assay buffer, as indicated above, was added to each well of the 96-well plates containing 5 µL of 10-mM compounds dissolved in DMSO. The 384-well black assay plates were prepared by distributing 2.5 µL of the diluted compounds into each well and sequentially adding the substrate (30 µL) and the enzyme (30 µL). Thus, the final screening concentration of the compounds was 10 µM (0.1% DMSO). The plates were then transferred to the plate reader, and the fluorescence intensities were monitored for at least 1 h with 0.5-min reading intervals.
For IC 50 determinations, the 10-mM compound solutions were first serially diluted in DMSO, and equal aliquots (5 µL) of each dilution were added to 15 µL of the assay buffer. All other procedures were performed as described above. Thus, in these experiments, the highest compound concentration was 100 µM, with serial 3-fold dilutions at a constant DMSO concentration of 1%.
Data fitting and manipulations
All curve fittings were performed with Prism 4 software (GraphPad, San Diego, CA), using built-in equations describing corresponding data models.
HTS quality was assessed using Z′ factor, 15 which describes a window between maximal and minimal signal compared to data variability inside the screening experiment. Z′ factor calculations were performed for each plate using data obtained from the plate columns reserved for caspase-3 without (Max signal) and in the presence of its tetrapeptide inhibitor, Ac-DEVD-CHO, (Min signal). Calculations were performed using the following equation:
where σ Max and σ Min are, respectively, standard deviations of maximal (Max) and minimal (Min) readings.
RESULTS
Primary screening
For assay quality control purposes and Z′ factor calculations, each 384-well plate contained 32 wells (columns A01-P01 and A02-P02) with the enzyme only (Max Enzyme Activity) and 32 wells (columns A23-P23 and A24-P24) with the enzyme and a 60-nM peptide inhibitor, Ac-DEVD-CHO (Min Enzyme Activity). Thus, for each plate, its own screening window had been established between the caspase-3 Max Enzyme Activity and Min Enzyme Activity.
The quality of the caspase-3 assay was very good (Z′ factor across all the plates tested was higher than 0.8). The primary screen of the selected compounds at a concentration of 10 µM revealed 299 hits (higher than 50% enzyme inhibition threshold). Thus, the focused library has produced a 1.9% hit rate, which is much better than the usual rate of 0.01% to 0.1% when diverse libraries are screened.
The hits discovered during the primary HTS screening campaign represented at least 11 new chemotypes, which have not been previously described as inhibitors of cysteine proteases. Two chemotype libraries, which produced potent inhibitors, are described elsewhere. 16, 17 Here we describe in more detail 2 new chemotypes found among the hits belonging to 8-sulfonyl-pyrrolo[3,4-c]quinoline-1,3-diones (SPQ), which are based on the general template I ( Table 1) .
First, we tested compounds of the chemotype 1 series of SPQ analogs, 4-methyl-8-(4-methyl-piperidine-1-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones, by varying content of the R group (Table 1) . There was a clear trend in inhibition potency of the compounds. More bulky lipophilic groups such as cycloheptyl and cyclohexyl substantially decreased the potency, and more polar and hydrophilic groups increased the potency. Next, we fixed the R-group of the chemotype 1 to the ethoxy substitute found in Novel Small-Molecule Caspase-3 Inhibitors the most potent compound, CD-001-0011, and analyzed a series of compounds by substituting the piperidine moiety in position 8 (Table 1) with primary amines of benzene and benzene derivatives (chemotype 2). For all studied compounds of the chemotype 2, no substantial differences were evident, although all of them were less potent than CD-001-0011.
Unlike known caspase-3 inhibitors, the compounds of the SPQ series have 2 electrophilic carbonyls that might serve as sites of nucleophilic attack by cysteine thiolates (Fig. 1) .
The CD-001-0011 (Table 1) , which exhibited fairly good caspase-3 inhibition potency (IC 50 ≈ 130 nM), was further charac-terized in the follow-up mechanistic, cell-based, and wholeorganism (zebrafish) antiapoptosis studies.
Mechanistic analysis of caspase-3 inhibition by CD-001-0011
Reversibility of the caspase-3 inhibition with CD-001-0011 was determined in the dilution experiments as described in the Materials and Methods section. From the data shown in with time to the level characteristic of the control (1×) samples. This indicates reversible interaction of CD-001-0011 with caspase-3. The dissociation half-life, estimated in accordance with an equation describing 1st-order dissociation kinetics, was approximately equal to 50 min. Competition studies were performed using 2 types of experiments. In one experimental setting, the CD-001-0011 inhibition concentration curves were registered at several substrate concentrations ( Fig. 3) . In an orthologous setting, the substrate concentration-dependent rates of enzyme activity were measured in the presence of different concentrations of CD-001-0011 ( Fig.  4) . Both experiments indicated noncompetitive inhibition. Inhibition experiments such as illustrated in Figure 3 revealed no rightward shift upon increasing the substrate concentration, which would be expected for competitive inhibition. In the classical Michaelis-Menten experiments (Fig. 4) , increases in inhibitor concentration lead to diminishing of V max , with no statistically significant changes in the K M values.
The selectivity profile of CD-001-0011 was assessed using 9 commercially available caspases, 1 through 9. Substrates and con-ditions used for each of the kinases are described in the Materials and Methods section. The results are presented in Figure 5 .
The results were grouped for caspases in accordance with their selectivity at the P4 site. 18 CD-001-0011 nonselectively inhibits caspases of group I with potencies in the range of 500 nM to 800 nM. It is approximately an order of magnitude less potent in inhibiting caspases of group III and shows some selectivity among members of the group II, with caspase-3 having the highest sensitivity (pIC 50 ≈ 7) among the caspases tested. The maximal difference in potencies covers 2 orders of magnitude ranging from about 10 µM (caspases 8 and 9, group III) to about 100 nM (caspase 3, group II). 
Antiapoptotic effect of CD-001-0011
Antiapoptotic activity of CD-001-0011 was determined in several cell lines and in a whole animal model (zebrafish). The cell apoptosis was induced by staurosporine in cell cultures and by retinoic acid in zebrafish, as described in the Materials and Methods section. Apoptosis in cells was measured as the suppression of Alamar Blue ® reduction rate after 24 to 48 h incubation with staurosporine or with the mixture of staurosporine and CD-001-0011. Zebrafish experiments were performed at Phylonix Pharmaceuticals, Inc. (Cambridge, MA) in accordance with the protocol described in the Materials and Methods section.
Both Table 2 and Figure 6A demonstrate the protective activity of CD-001-0011 against staurosporine-induced apoptosis in cell cultures. Apoptosis leads to drastic changes (rounding and shrinkage) in cell morphology (Fig. 6A, ii) , increased intracellular capase-3/7 activity (data not shown), and diminished rate of Alamar Blue ® reduction. CD-001-0011 effectively prevented the staurosporine-induced cell morphology changes (compare Fig.  6A , ii and iii) and staurosporine-induced cell death in several cell lines ( Table 2) .
CD-001-0011 also effectively blocked retinoic acid-induced apoptosis of neuronal cells in a whole animal (zebrafish). The apoptotic cells appear as black dots in the forebrain (small arrow in Fig. 6B, II) . In the presence of CD-001-0011, retinoic acid failed to induce neuronal cell apoptosis as evidenced by the absence of the black dots in the forebrain (Fig. 6B, III and IV) . The compound also effectively prevented retinoic acid-induced defects in developing yolk sack (large arrow, Fig. 6B, II) .
In the cell-and zebrafish-based assays, much higher concentrations of the inhibitor were needed to achieve protective effect as compared with inhibition experiments using purified enzyme. A similar difference between caspase-3 inhibition and whole-cell antiapoptotic potency was shown for isatin sulfonamides 7 and anilinoquinazolines. 8 Such a difference could be due to many factors, including poor cell membrane permeability, metabolic transformation inside the cells, protein binding, and so forth. 7, 8 At least for isatin sulfonamides, it was shown that cytosol binding is responsible for lower potency in cell-based assay versus isolated enzyme assay. 7
DISCUSSION
Cysteine proteases play an important role in different pathologies and are expected to be valuable therapeutic and antiviral targets. Efforts to identify small-molecule inhibitors are well under way. 10 The SPQs are structurally distinct from other known classes of nonpeptide caspase-3 inhibitors, including isatin sulfonamides. Unlike previously reported inhibitors, they possess 2 potential sites for nucleophilic attack by cysteinyl thiolate (see Fig. 1 ). Our data show that the interaction of the inhibitor with caspase-3 is reversible though noncompetitive, which raises the possibility that it might act allosterically through interaction with sulfhydryl group(s) distinct from the active site. Indeed, it was shown that caspases can also be regulated by protein thiol modification at sites other than the active site cysteine. 19 Thus, Cys 244, located near the active site of caspase-1, is believed to be essential for the caspase-1 activity and is a target of the enzyme inhibition by thimerosal. 20 The authors are not aware of any existing data that clarify the role of other than active-site cysteinyls in caspase-3 activity. However, Hampton and others 21 have shown that inactivation of caspase-3 with hydrogen peroxide substantially increases when a substrate is present before hydrogen peroxide is added. It is difficult to explain such behavior by increased susceptibility of the active site thiol to the peroxide, which is accessible to solvent in the groove of the active site formed by 4 loops when no substrate is present 22 (Fig. 7A) and is inaccessible or partially accessible to a solvent in the bound state 23 (when a peptide is present in its active site; Fig. 7B ).
Caspase-3 has total of 7 cysteinyls, although some of them are buried deep in the molecule. Still, at least 3 of them (excluding the one in active site) are readily accessible to water and hence to potential oxidation. One can speculate that cysteinyl thiol outside the active site might become more susceptible to the hydroperoxide in the presence of substrate and that its oxidation leads to enzyme inactivation. Our data showing a noncompetitive nature of the caspase-3 inhibition with CD-001-0011 also indicate that the inhibitor may interact with a nonactive site thiol, leading to allosteric enzyme inactivation. Our data also show that the interaction of CD-001-0011 with caspase-3 is reversible (see Fig. 2 ), although, unlike isatin sulphonomides, 7 with a slow dissociation rate (τ ≈ 50 min). From a pharmacokinetics perspective, the slow-off rate should be an advantageous feature of a potential antiapoptotic drug, as it would tend to maintain caspase in the inhibited state, even if the drug has fast elimination rates from the blood. CD-001-0011 effectively prevents apoptosis in cell cultures as well as in whole organism, zebrafish (Fig. 6) . Like all other smallmolecule caspase-3 inhibitors, 7-9,24 CD-001-0011 exhibits substantially lower potency in preventing apoptosis than that of inhibiting caspase-3. Several possibilities are discussed for such a reduction in potency: cell membrane permeability, binding to or electrophilic interactions with cytosolic proteins, or other, as yet unidentified, mechanisms. Thus, the peptidomimetic caspase-3 inhibitor devel-oped by Micale and others 24 has a K i value of 36 nM (10 times less potent than tetrapeptide aldehyde, Ac-DEVD-CHO), whereas 50% inhibition of etoposide-induced apoptosis of SH-SY5Y cells was achieved at the same concentration as the peptide, approximately 150 µM. From these data, the authors concluded that the peptide mimetic had better cell membrane permeability than the peptide did. The data also revealed a striking difference in potency of the peptidomimetics to inhibit intracellular caspase-3/7 activity and prevent apoptosis (see Fig. 3 in Micale and others 24 ). Both the peptide mimetic and Ac-DEVD-CHO at a concentration of 50 µM showed a very subtle antiapoptotic effect while totally inhibiting intracellular caspase-3. In interpreting these data, one should keep in mind that both the Ac-DEVD-CHO and the peptide mimetic are highly caspase-3-selective inhibitors, and the failure to effectively block apoptosis may indicate that other caspases might be involved in the cell death.
CD-001-0011 has shown an interesting selectivity profile, having higher potencies for caspases of group I and group II and low potency for caspases of group III (Fig. 5) . Inside group III, CD-001-0011 displays the highest potency toward caspase-3 and an order of magnitude lower potency toward caspase-2. At present, though a general quest is being directed to identifying and developing highly selective caspase-3 inhibitors as potential drug candidates, there is not enough preclinical and clinical information to suggest that the high selectivity would be of real advantage. Broadspectrum inhibitors could be used for a multiplicity of therapeutic areas. Indeed, a role of caspase-1 inhibitors has been thought to be mainly useful in treatment of inflammation. However, there are indications that caspase-1 might also be a key enzyme in neurodegenerative disease-induced neuronal cell apoptosis. 25 Other caspases, in particular caspase-3, can also be activated 26 in such diseases. Therefore, discovery of small-molecule caspase inhibitors with different selectivity profiles could be important in understanding pathologies and could lead to a development of highly effective drugs. Journal of Biomolecular Screening 11(3); 2006   FIG. 7. (A) Three-dimensional structure of an unligated caspase-3 at 1.9 Å resolution. 22 Both chain A and B are shown in magenta. (B) Three-dimensional structure of the caspase-3 in complex with AcDEVD-CHO peptide at 2.5 Å resolution. 23 Chain A is shown in magenta, chain B is shown in blue, and peptide is shown in brown. Active site and C-terminal cysteinyl moieties are shown in yellow in both panels.
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